STENTYS Revenues for the First 9 Months of 2014 up 16.9%

STENTYS (Paris:STNT) (FR0010949404 — STNT), a medical technology company commercializing, in Europe, the world's first and only Self-Apposing^® stent to treat acute myocardial infarction (AMI), today announces revenues for the third-quarter and nine-months ended September 30, 2014.

• Change in third-quarter and nine-month revenues*

* Data reviewed by the statutory auditors

STENTYS recorded revenues of €876.5 thousand over the third quarter of 2014, up 14.1% compared with the third quarter of 2013. This growth was driven by sales of its current range of self-apposing stents both directly via the Company and through its network of distribution partners in various regions around the world.

For the first nine months of the year, revenues totaled €2.8 million, up 16.9% compared with the same period of 2013.

• A sound cash position

At September 30, 2014, STENTYS had cash and equivalents totaling €20 million compared with €23.1 million at June 30, 2014.

Gonzague Issenmann, Chief Executive Officer and co-founder of STENTYS, explains: "The quarterly sales growth is progressing smoothly with our current product portfolio, as illustrated by the latest success with the regional tender in the Middle East for 2015. We intend to pursue our sales coverage strategy in high-potential geographies by creating strong partnerships with the best local distributors.”

About STENTYS
STENTYS is developing and commercializing innovative solutions for the treatment of patients with acute myocardial infarction (AMI, or heart attack) and complex coronary artery disease. STENTYS’s Self-Apposing® Stents are designed to adapt to vessels with ambiguous or fluctuating diameters, particularly in the post-infarction phase, in order to prevent the malapposition problems associated with conventional stents. In the APPOSITION III clinical trial, STENTYS stents demonstrated a very low one year mortality rate among 1,000 high-risk AMI patients when compared to recent studies with conventional stents. More information is available at www.stentys.com.

STENTYS is listed on Comp. B of Euronext Paris
ISIN: FR0010949404 – Ticker: STNT